VSY Biotechnology

vsybiotechnology.com

As VSY Biotechnology we are a progressive and innovative company that focuses on customer satisfaction by creating superior state of the art ophthalmology products designed and manufactured to greatly enhance and improve vision for our wide range of patients around the globe. All our products go through rigorous and comprehensive research and development to ensure manufacturing efficiency and the highest optic quality. With our superior product line and our sterling focus on our customers needs, we at VSY Biotechnology believe that the future could not be clearer.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

REGENERON TO ACQUIRE DECIBEL THERAPEUTICS, STRENGTHENING GENE THERAPY AND HEARING LOSS PROGRAMS

Globenewswire | August 10, 2023

news image

Regeneron Pharmaceuticals, Inc. and Decibel Therapeutics, Inc. a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced a definitive agreement for the acquisition of Decibel by Regeneron at a price of $4.00 per share of Decibel common stock payable in cash at closing, with an additional non-tradeable contingent value right (CVR) to receive up to $3.50 per share in cash upon achieveme...

Read More

Industrial Impact

NEW MENARINI SILICON BIOSYSTEMS PARTNERSHIP WITH ALIVIO HEALTH EXPANDS PATIENT ACCESS TO CELLSEARCH® LIQUID BIOPSY TESTS

PRNewswire | May 22, 2023

news image

Menarini Silicon Biosystems (MSB), a pioneer of liquid biopsy and single cell technologies, announced today its partnership with Alivio Health. This new agreement opens the door to preferred access for Alivio Health clients and providers to the valuable information offered by the CELLSEARCH CTC tests, which allow longitudinal monitoring of cancer patients at any time during the course of the disease. Starting from a simple blood draw, CELLSEARCH CTC tests provide valuable information on a ...

Read More

Cell and Gene Therapy

SQZ BIOTECHNOLOGIES AND COLLABORATORS PUBLISH TECHNOLOGY REVIEW ON SQZ® APCS AND EFFECTIVE CD8 T CELL ACTIVATION

SQZ Biotechnologies | July 13, 2022

news image

SQZ Biotechnologies Company focused on unlocking the full potential of cell therapies for multiple therapeutic areas, announced the publication of a technical review examining the ability of SQZ® Antigen Presenting Cells to activate CD8 T cells through MHC-I antigen presentation, an approach that may enable a more powerful T cell response and infiltration into solid tumors. Published in ESMO’s Immuno-Oncology and Technology journal, the review further explores the advantages of t...

Read More

Medical, Industry Outlook

MUSTANG BIO ANNOUNCES FIRST DATA FROM ONGOING MULTICENTER PHASE 1/2 CLINICAL TRIAL EVALUATING MB-106 CAR-T CELL THERAPY

Globenewswire | August 17, 2023

news image

Mustang Bio Inc. a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced the first data from the indolent lymphoma cohort of the Company’s ongoing multicenter Phase 1/2 clinical trial evaluating MB-106, a first-in-class CD20-targeted, autologous CAR-T cell therapy for the treatment of relapsed or refractory B-cell non-...

Read More
news image

Medical

REGENERON TO ACQUIRE DECIBEL THERAPEUTICS, STRENGTHENING GENE THERAPY AND HEARING LOSS PROGRAMS

Globenewswire | August 10, 2023

Regeneron Pharmaceuticals, Inc. and Decibel Therapeutics, Inc. a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced a definitive agreement for the acquisition of Decibel by Regeneron at a price of $4.00 per share of Decibel common stock payable in cash at closing, with an additional non-tradeable contingent value right (CVR) to receive up to $3.50 per share in cash upon achieveme...

Read More
news image

Industrial Impact

NEW MENARINI SILICON BIOSYSTEMS PARTNERSHIP WITH ALIVIO HEALTH EXPANDS PATIENT ACCESS TO CELLSEARCH® LIQUID BIOPSY TESTS

PRNewswire | May 22, 2023

Menarini Silicon Biosystems (MSB), a pioneer of liquid biopsy and single cell technologies, announced today its partnership with Alivio Health. This new agreement opens the door to preferred access for Alivio Health clients and providers to the valuable information offered by the CELLSEARCH CTC tests, which allow longitudinal monitoring of cancer patients at any time during the course of the disease. Starting from a simple blood draw, CELLSEARCH CTC tests provide valuable information on a ...

Read More
news image

Cell and Gene Therapy

SQZ BIOTECHNOLOGIES AND COLLABORATORS PUBLISH TECHNOLOGY REVIEW ON SQZ® APCS AND EFFECTIVE CD8 T CELL ACTIVATION

SQZ Biotechnologies | July 13, 2022

SQZ Biotechnologies Company focused on unlocking the full potential of cell therapies for multiple therapeutic areas, announced the publication of a technical review examining the ability of SQZ® Antigen Presenting Cells to activate CD8 T cells through MHC-I antigen presentation, an approach that may enable a more powerful T cell response and infiltration into solid tumors. Published in ESMO’s Immuno-Oncology and Technology journal, the review further explores the advantages of t...

Read More
news image

Medical, Industry Outlook

MUSTANG BIO ANNOUNCES FIRST DATA FROM ONGOING MULTICENTER PHASE 1/2 CLINICAL TRIAL EVALUATING MB-106 CAR-T CELL THERAPY

Globenewswire | August 17, 2023

Mustang Bio Inc. a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced the first data from the indolent lymphoma cohort of the Company’s ongoing multicenter Phase 1/2 clinical trial evaluating MB-106, a first-in-class CD20-targeted, autologous CAR-T cell therapy for the treatment of relapsed or refractory B-cell non-...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us